Mandate

Vinge advises Fouriertransform in connection investment in El-Forest

July 06, 2010

Vinge has advised Fouriertransform in connection with its investment in El-Forest. El-Forest has developed the world’s first forestry machine that uses energy efficient electric-hybrid technology. The technology gives rise to several environmental improvement measures. The investment is taking place through a directed new share issue pursuant to which Fouriertransform will become the largest individual shareholder. El-Forest’s forestry machine has a unique and patented track following and hybrid operation system which reduces fuel consumption, carbon dioxide emissions and reduces damage to forests due to the light weight of the machine.

Fouriertransform is a state-owned venture capital company which commercially supports innovative companies and entrepreneurs who can contribute to stimulating the Swedish vehicle industry.

Fouriertransform was represented in the negotiations by partner Bo Adrianzon and associate Johan Steen. Associates Sofia Berg and Adam Weissbach (IP) assisted in the due diligence phase.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026